Skip to main content

Sickle Cell Disease: A Global View

From the 2021 Joint Annual Meeting (recorded 6/29/2021)
Presented by Tim Randolph, PhD, MT(ASCP)

Sickle cell disease is the most common monogeneic disease worldwide, yet patient outcomes vary widely. Mortality rates by age 5 years have been reported from 1% to 90%. This session will discuss global distribution and the variables that affect morbidity and mortality outcomes to include potentially curative therapeutic approaches.

LEARNING OBJECTIVES
At the conclusion of this presentation, participants will be able to:

  • Describe the basic pathophysiology of sickle cell disease
  • Identify the global distribution of sickle cell disease and factors that affect outcomes
  • Summarize the major therapeutic interventions to include potentially curative therapies

CE ACCREDITATION
ASCLS is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. One (1) P.A.C.E. ® contact hour and one (1) Florida credit hour in the area of General (Hematology) will be awarded to participants. ASCLS P.A.C.E.® is accepted by the ASCP/ASCLS/AGT Board of Certification and all states, including Florida and California, as an approved provider of continuing education for recertification and licensure. ASCLS is an approved provider with CE Broker for Florida licensees.

LEVEL OF INSTRUCTION
This Intermediate-level program is appropriate for laboratory professionals working in clinical, public health and academic settings.